Tp53 and Kras Mutations As Markers of Outcome of Adjuvant Cisplatin-Based Chemotherapy in Completely Resected Cancer Trial (Ialt) Biological Program.Non-Small-Cell Lung Cancer (Nsclc): the International Adjuvant Lung

Tp53 and Kras Mutations As Markers of Outcome of Adjuvant Cisplatin-Based Chemotherapy in Completely Resected Cancer Trial (Ialt) Biological Program.Non-Small-Cell Lung Cancer (Nsclc): the International Adjuvant Lung

2008 Journal of Clinical Oncology

Ma, X. | Vataire, A.L. | Sun, H. | Dunant, A. | Brambilla, E. | Soria, J.C. | Filipits, M. | Hainaut, P. | Volume: 26 [15S Suppl.], Issue: 1085, Pages: ,